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The current version of the human immunome network consists of nearly 1400 interactions involving approximately 600 proteins.
Intermolecular interactions mediated by proline-rich motifs (PRMs) are observed in many facets of the immune response.
The proline-rich regions are known to preferentially adopt a polyproline type II helical conformation, an extended structure
that facilitates transient intermolecular interactions such as signal transduction, antigen recognition, cell-cell communication
and cytoskeletal organization. The propensity of both the side chain and the backbone carbonyls of the polyproline type II
helix to participate in the interface interaction makes it an excellent recognition motif. An advantage of such distinct chemical
features is that the interactions can be discriminatory even in the absence of high aﬃnities. Indeed, the immune response is
mediatedbywell-orchestratedlow-aﬃnityshort-durationintermolecularinteractions.Theproline-richregionsarepredominantly
localized in the solvent-exposed regions such as the loops, intrinsically disordered regions, or between domains that constitute the
intermolecular interface. Peptide mimics of the PRM have been suggested as potential antagonists of intermolecular interactions.
In this paper, we discuss novel PRM-mediated interactions in the human immunome that potentially serve as attractive targets for
immunomodulation and drug development for inﬂammatory and autoimmune pathologies.
1. Protein-Protein Interactions
Protein-protein interactions (PPIs) are critical for most
biological functions and cellular processes [1, 2]. Under
appropriate environmental conditions, the PPIs take place
through an interface governed by shape, chemical com-
plementarity, and ﬂexibility of the interacting molecules.
Diﬀerent types of PPIs have been described. Homo- or
heterologous oligomeric PPI complexes represent isologous
or heterologous association of identical protein units. PPI
complexes of interdependent protomer units are referred to
as obligate complexes as opposed to nonobligate complexes
that occur independently [3, 4]. The strength of PPI is
represented by the dissociation constant (KD) expressed in
molar concentration and derived from the ratio between
the dissociation and association rate constants. Based on
duration and aﬃnity, PPIs can be classiﬁed as strong
interactions that exhibit KD values with μM concentrations
and weak or transient interactions with values in the mM
or higher concentrations. Transient PPIs are further divided
into strong and weak transient interactions. While strong
transient PPIs require a molecular trigger such as ligand
binding to shift the oligomeric equilibrium, weak transient
interactions are mediated by binding between a few critical
residues [3, 5].
Traditionally, PPIs are thought to be mediated by “lock
and key” or “induced-ﬁt” interaction between large struc-
tured domains [6]. However, characterization of increasing
numbers of protein sequences and structures has suggested
that the interacting modules of multidomain proteins can2 International Journal of Peptides
be distinguished as globular domains, as short peptide
functional sites, and as long peptides that interact with their
partners over extensive regions. Thus, three distinct protein-
protein interfaces are recognized [7]. While the evolution-
arily conserved domain-domain interfaces are large and
relatively stable, the evolutionarily plastic domain peptide
interfaces are smaller and transient [8–10]. Protein interac-
tion domains can be classiﬁed based on sequence homology,
ligand-binding properties, or structural similarity [11].
Thus, a typical class of ligand binding proteins may contain
a variety of protein interaction domains that recognize a
common ligand, whereas a family classiﬁed based on se-
quence homology contains a single fold that may recognize a
variety of ligands. Some families function in a narrow cellu-
lar context, while others participate in a diverse range of
processes [11, 12].
2. Protein:PeptideInteractions:
LinearMotifsandMolecularRecognition
Features(MoRFs)
Interactions between globular proteins or domains and pep-
tide have been investigated in parallel using biological data
and/or computational methods [7, 13–19]. Short segments
of structured binding sites within long disordered regions
of proteins are referred to as linear motifs (LMs) or as
molecular recognition features (MoRFs) [13–15, 18]. While
LMs are identiﬁed/predicted by sequence patterns, MoRFs
are identiﬁed by sequence features associated with disorder
prediction [13, 14, 17, 18].
A systematic survey of LM-mediated protein interactions
estimated that 15–40% of all interactions in a typical eukary-
otic cell are mediated through protein-peptide interactions
[20]. Predictions over nine proteomes of MoRFs that often
form α-helices upon binding indicate that about 44 ± 4% of
eukaryotic proteins contain potential helix-forming MoRFs
[21]. These LM and MoRF frequency estimates concur
in the suggestion that a large fraction of macromolecular
c o m p l e x e si sa ﬀected either directly or indirectly by peptide-
binding events. The protein interface is predeﬁned and
ready to accommodate the binding peptide. For eﬃcient
interaction, the peptide “scans” the protein surface for a
large enough pocket into which it anchors through a small
number of residues or core motif that contribute maximally
to the free energy of binding [22]. The hot spot residues
show a tendency to be localized in the center, and the
number of hot spots is partially dependent on the length
of the interacting motif [14, 23]. In general, the average
solvent-accessible surface area that is buried upon peptide
binding is less than half the area buried in protein-protein
complexes. Furthermore, the peptides tend to bind in a more
planar fashion, optimize hydrogen bonds, and display better
packing than proteins at the interface [10, 20].
3.AminoAcidPropensitiesinLMs
In terms of amino acid composition, the sequence of LMs
canbedistinguishedintotypicalpatterns.EachLMpossesses
a set of conserved residues having restricted identities that
serve as speciﬁcity determinants and a second set of fully
variable residues that likely act as spacers [14, 24]. The
spacers and ﬂanking regions exhibit preferential presence of
disorder promoting charged residues. The restricted identi-
ties of LM are enriched in proline as well as in hydropho-
bic residues including phenylalanine, leucine, tryptophan,
tyrosine, and isoleucine [14, 25] .T h er e l a t i v ep a u c i t yo f
glycine and alanine in the LMs may represent strategies
to simultaneously curb excessive ﬂexibility and restrict the
tendency to form strong secondary structural elements [25–
27]. Systematic analyses suggested that, as compared to
the general disordered regions, MoRFs are also enriched in
hydrophobic residues, in particular the aromatic residues
[15, 18, 25]. In many cases, LMs and MoRFs identify the
same region of sequence. The function of LMs is essentially
embodied in the primary amino acid sequence independent
of tertiary structure and is strongly context dependent
which deﬁnes the natural constraints that act on these
motifs. Within protein structures, LMs are predominantly
observed in the solvent-exposed regions such as the loops, in
intrinsically disordered regions or between deﬁned domains
[28].
4.Signiﬁcanceof ProlineinLMs
Of special signiﬁcance is the preponderance of proline both
in the conserved identities and in the ﬂanking regions of
LMs [24, 25]. Among the naturally occurring amino acids,
proline is unique in several features. It is the only residue
with substituted amide nitrogen. Proteins that recognize
the δ carbon on the substituted amide nitrogen within the
context of the otherwise standard peptide backbone can
selectpreciselyforprolineatagivenpositionwithoutmaking
extended contacts with the rest of the side chain [29]. This
facilitates sequence-speciﬁc recognition without requiring a
particularly high-aﬃnity interaction [30]. Such speciﬁc and
weakbindingsareimportantforcellularcommunicationand
signaling functions that require rapidly reversible interac-
tions [31].
Proline is the only naturally occurring amino acid in
which the side chain atoms form a pyrrolidine ring with
the backbone atoms. This cyclic structure mediates the slow
isomerization between cis/trans conformations [32]. The
polyproline stretches can adopt two unique helical con-
formations, I and II [33]. Polyproline type I (PPI)i sa
right-handed helix consisting of cis-prolines. While poly-L
proline in apolar solvents can adopt the PPI conformation,
there is paucity of PPI helical segments in proteins [33,
34]. PPII helix is a left-handed helix, consists of proline
in trans-conformation, but also accommodates frequently
other amino acids such as glutamine, serine, and arginine
[35, 36]. With three residues per turn, the PPII helix is an
extended structure and has an overall shape resembling a
triangular prism. PPII helices are widely distributed in the
eukaryotic proteome and hence are of greater biological
signiﬁcance [37, 38].International Journal of Peptides 3
The unusual shape of the proline side chain imposes
structural constraints on adjacent residues such that the pro-
line rich motif (PRM) preferentially adopts the left-handed
PPII helicalconformation[37,39].InPPII helix,boththeside
chainsandthebackbonecarbonylspointoutfromthehelical
axis into solution at regular intervals [40]. Furthermore, the
lack of intramolecular hydrogen bonds primarily due to the
absence of a backbone hydrogen-bond donor on proline
leaves these carbonyls free to participate in intermolecular
hydrogen bonds. Thus, both side chains and carbonyls can
easily be “read” by interacting proteins making PPII helix an
excellent recognition motif [37]. In addition, since the back-
bone conformation is already restricted, the entropic cost of
binding is reduced [41]. In contrast to the enthalpy-induced
associations such as the lock and key model, PPII helices are
e n t r o p yd r i v e na n db e h a v ea s“ a d a p t a b l eg l o v e s ”i no r d e r
to obtain the correct recognition. Indeed, in a recent study
that reported signiﬁcantly lower conﬁgurational entropy for
known peptide inhibitors, polyproline peptides were among
those with lowest entropy values [42]. While the intrinsic
properties of the proline facilitate the PPII helix formation,
the conformation is potentially stabilized by the surrounding
water molecules supporting the preponderance of PRM in
solvent exposed loops/disordered regions of proteins [37–
39]. Furthermore, it has been observed that, in addition to
the enrichment of proline and hydrophobic residues, the
LMs are also rich in charged residues including arginine
and aspartic acid [24, 25]. Positively charged residues both
local and nonlocal to the PPII helices satisfy the H-bond
donorpotentialofthemain-chaincarbonylsandstabilizethe
PPII conformation [43]. An advantage of focusing on such
distinct chemical features is that such interactions can be
discriminatory without resorting to extremely high aﬃnities
[37]. Indeed, PRM-mediated interactions exhibit fast on
and oﬀ rates of binding adopted for eﬀective control and
regulatory functions [31, 38].
5. Natureof PRM-Binding Domain (PRD)
The binding between the PRM and the protein domains
reliesoninteractionswithcore-ﬂankingepitopesofthemotif
and the PRD interface residues to achieve the necessary
speciﬁcities [14, 25, 44]. The amino and carboxyl termini
of the PRD are generally located relatively close together
allowing the domains to slot into their respective host
proteins with minimal disruption of the overall protein
structure [45]. Structurally, the PRD themselves are found
in exposed and accessible regions to recruit target proteins.
The PRDs are enriched in aromatic residues that often
selectively interact with the critical proline of the PRM in
the binding interface. The planar structure of the aromatic
side chains appears to be highly complementary to the ridges
and grooves presented on the PPII helix formed by the PRM
[45, 46].
Summarizing, if a recognition event involves the dis-
tinctive property of proline among the 20 natural amino
acids, the interaction does not have to be of particularly high
aﬃnity to be selective [47]. The beneﬁts of weak, but
speciﬁc, interactions in intracellular signaling pathways may
help explain the preponderance of proline-based recognition
motifs in the eukaryotic proteome [48]. Indeed, a recent
survey revealed an abundance of the polyproline motif
“PXXP” in various gene ontology groups of proteins includ-
ing enzymes, cytoskeletal proteins, nucleic acid-binding
proteins, transport proteins, splicing factors, metal-binding
proteins, and ribosomal proteins suggesting an evolutionary
conservation of protein-protein networks centered on PRMs
[49].
6. PRD:PRM Interactionsin
the ImmunieResponses
The human immunome network elicited so far consists of
nearly 1400 interactions involving approximately 600 pro-
teins [50]. Several protein:peptide interactions have been
shown to be pivotal for the formation of molecular assem-
blies of functional complexes that include membrane bound
receptors, cytoplasmic signaling molecules, and transcrip-
tional regulatory proteins [51–53]. The life time of the
protein complexes as well as the regulatory processes are
tightly controlled for proper functioning [29, 44].
PRM-mediated intermolecular interactions are observed
in many facets of the immune response including antigen
recognition, cell-cell communication, and signaling [46].
Stimulation of lymphocytes with a speciﬁc antigen initiates
a cascade of signal transduction events that are integrated by
numerousadapterproteinswhichfunctiontoestablishlarger
protein complexes and promote complete activation. Many
of these adapter proteins possess speciﬁc protein domains
such as the Src homology 3 (SH3) domains and the WW
(named for two tryptophans (W)) domains that selectively
recognize proline rich regions in their interacting partners
[12, 46]. In addition, many cell surface and intracellular
proteins in the immunome exhibit one or two proline-rich
regions that interact with highly conserved hydrophobic
residues in their binding partners and mediate transient
protein-protein interactions [14, 44, 48]. The advantages of
transient protein-peptide interactions for functioning of the
immune system can be enumerated as follows.
(1) The small interface between the peptides and their
protein domain partners facilitates low-aﬃnity weak
interactions that are easily formed and disrupted to
regulate cellular responses. Indeed cell surface re-
ceptors that mediate immune responses are often
coupled to intracellular signaling pathways by recog-
nition of modular protein interaction domains that
bind a short LM for example, CD2:CD2BP interac-
tion (KD =μM) [54].
(2) One protein can bind multiple peptides providing
an elegant mechanism that uses transient interac-
tions for bringing together diﬀerent combinations
o fc o m p l e x e se a c hw i t hd i ﬀerent functions leading
to a diﬀerent signal and response, for example,
CD80:CD28/CD152 interactions [55].4 International Journal of Peptides
(3) The low-aﬃnity binding allows for large number
of interactions of short durations ranging between
10s and 100s decreasing the possibility of sustained
adherence and facilitating ﬂeeting contacts critical
for cell-cell communications such as the interactions
between the antigen presenting cells and the T cells
mediated by integrins [56, 57].
In this paper, we discuss novel PRD:PRM interactions
that could potentially serve as attractive targets for immun-
omodulation and drug development for inﬂammatory and
autoimmune pathologies. The paper does not include the
widelyrecognizedSH3domain:peptideinteractions.Readers
interested in these interactions are referred to the excellent
reviews [45, 58].
7. PRD:PRM Interactions in
Cell Surface Immunome
Proteins located at the surface of immune cells are of par-
ticular signiﬁcance in migration, in speciﬁc antigen recog-
nition, in modulating the function of receptors for immune
response mediators such as the cytokines as well as in
highly focused ﬁne control of intercellular interactions
between proteins on opposing cells. Many such interactions
have been characterized using monoclonal antibodies [51,
59]. Diﬀerential expression and/or function of cell surface
proteome in health and disease have been reported in several
immune-mediated pathologies substantiating the potential
role of select immune cell surfaceproteins as excellent targets
for diagnostic and therapeutic interventions [60].
8.T-CellCostimulatoryReceptor:
LigandInteractions
A manually curated database suggested that over 20% of
the human cell surface immunome consists of members of
the immunoglobulin superfamily which includes the T-cell
costimulatorymolecules[61,62].Inadditiontotheantigenic
stimulation, complete activation of lymphocytes requires
costimulatoryreceptor-ligandinteractionsthatmodulatethe
strength, course, and duration of the immune response
[63, 64]. One of the better characterized complexes include
the interactions between the costimulatory receptors CD28/
CD152 or ICOS expressed on T cells and the CD80/CD86
and ICOSL ligands on the antigen presenting cells. Struc-
turally, the CD28, CD152, and ICOS are composed of a
single extracellular IgV domain linked to a stalk region
and a transmembrane segment followed by a relatively
short cytoplasmic tail, which contains at least one tyrosine-
based signaling motif [65]. The receptors exhibit signiﬁcant
homology in primary sequence and share a consensus
sequenceconsisting ofthreeconsecutiveprolinesinthecom-
plementarity determining region-3 like region/FG loop [56].
In CD28 and CD152, these prolines are embedded within
the MYPPPY sequence, while, in ICOS, they are embedded
in the FDPPPF sequence. Mutagenesis experiments indicate
that the polyproline motif is essential for the binding of
CD152, CD28, and ICOS to their respective ligands [66,
67]. The crystal structures of the murine CD152 bound to
CD80 or CD86 reveal that the binding interface is formed
predominately by contacts between the MYPPPY sequence
of the CD152 FG loop and a concave surface on the front
sheet of the CD80 ligand (Figure 1). The three proline
residues in the polyproline motif adopt a unique open cis-
trans-cis main chain conﬁguration that exhibits geometric
complementarity to the binding pocket of the ligand [62,
68]. Secondary structure prediction by PROSS suggests that
the second proline of CD152 in the bound complex with
CD80 adopts PPII helical conformation with the φ and
Ψ angles of −76 and 164.6, respectively [69, 70]. In the
molecular model of ICOS built using the solution structure
of CD152 as template, the critical proline that interacts
with the ICOSL binding interface exhibits φ and Ψ angles
of −53.4 and 167.4, respectively [71]( T a b l e s1 and 2;
Figure 1). The sequence and structural homology together
with functional similarity of the FG loops suggest that
these receptors share a common mode of recognition for
their ligands. The ectodomains of the CD80, CD86, and
ICOSL possess a membrane proximal IgC and a distal IgV
domain that makes substantial contact with the solvent
exposed polyproline motif in the FG loop of the receptors
through a surface with considerable hydrophobic character
[71–73]. The extended PPII helical conformation facilitates
the backbone atoms of the PRM to form hydrogen bonds
with the conserved tyrosine at the CD80/ICOSL interface
[30, 37, 68]. Intriguingly, it has been suggested that the
presence of phenylalanine, a more hydrophobic and poor
hydrogen bond acceptor/donor, in the binding interface of
CD86 perhaps contributes to the absence of PPII helical
conformation and lower aﬃnity for the interactions between
CD152 and CD86 [73]. Thus, the local environment of the
CD80 binding pocket and the orientation of the functionally
important proline in the PRM of CD152 may account for the
diﬀerence in the strength of interaction between the CD152
and the CD80/CD86. Knowledge derived from the contact
preferences of amino acids at PPI interface and the residue
propensity to form PPII helix has been adopted in the design
of a small peptide, the CD80-competitive antagonist peptide
(CD80-CAP) that mimics the ligand binding conformation
of the receptor and inhibits CD28/CD152:CD80 interactions
[69]( Figure 1). Treatment with CD80-CAP suppressed T-
cell-mediated inﬂammatory responses in mouse models of
rheumatoid arthritis, multiple sclerosis, and inﬂammatory
bowel disease [74–76].
9. PRM:PRD Interactionsin the Cytoskeleton
Eﬃcient accomplishment of immune responses in inﬂam-
mation and infection requires a ﬁnely regulated cytoskele-
ton to enable cellular membrane reorganization, receptor
localization, and recruitment of signaling molecules, all
ofwhicharecrucialforimmunecellactivation,proliferation,
secretion, migration, and survival [77]. The cytoskeleton
consists of ﬁlamentous structures composed mainly of actin,
vimentin, and tubulin. Signaling from cell surface receptorsInternational Journal of Peptides 5
Table 1: The dihedral angles of the proline-rich motifs in selected immune-response-related proteins.
Class Motif Critical proline
Cell surface proteins
CD152 Phi Psi
Mouse 1DQT MYPPPY −84 167
Human 1I8L MYPPPY −76 164.6
CD28
Mouse Model MYPPPY −53.4 166.5
Human MYPPPY −55.4 165.3
ICOS
Mouse Model FDPPP −53.4 167.4
Human FDPPP −83.9 124.2
Cytoskeletal proteins WIP 2IFS LPPP −65.9 157.3
1MKE LPPP −75 158.1
Transcriptional factors
GILZ
Human Molecular Model PEAP −67.5 142.5
Mouse PEAP −72.5 162.3
SMRT
Human 2ODD PPP −70 158.4
Table 2: The proline-rich motif (PRM) and the proline-rich motif binding (PRB) domain in immune-related proteins.
Protein receptor PRM PRM interactant PRD critical residue Evidence
Membrane associated
CD28 MYPPPY CD80 Y71 Mutagenesis
CD152 MYPPPY CD86 F Mutagenesis, structural analysis
ICOS FDPPP ICOSL Y53 Mutagenesis, molecular model
Cytoplasmic WIP LPPP WASP WHI1 domain, W54 Structural analysis
Signal transduction GILZ PXX p65 TAD (F534. F542) Immunoprecipitation
Transcriptional cofactors
p53 PXXP p300 (SPC1 192–337)
SPC-2 (1737–1913) ChIP
SMRT PXLXP p65 TAD GST pull-down assays
SMRT MCTF MYND domain Mutagenesis
EA1 MYND domain Solution structure
ETO MYND domain Solution structure
Myc-related cellular transcription factor; viral oncoproteins EA1; ETO (a nuclear corepressor protein) chromatin immunoprecipitation.
and migration are mediated by rapid assembly of actin
ﬁlaments predominantly at the plasma membrane or cor-
tical cytoskeleton. The assembly of cytoskeletal network
is regulated by multiple classes of actin binding proteins
that initiate, polymerize, sever, depolymerize, and terminate
ﬁlament formation [78]. The interaction between cytoskele-
tal binding proteins and ﬁbers is often transient and of
low aﬃnity. Recently, alterations in regulators of cortical
actin cytoskeletal proteins have been implicated in immune
deﬁciency and autoimmune diseases [79].
10.Wiskott-Aldrich Syndrome Protein (WASP):
WASP-InteractingProtein(WIP) Binding
The importance of actin-mediated cytoskeletal regulation in
humans is exempliﬁed by Wiskott-Aldrich syndrome (WAS),
an immune deﬁciency disease characterized by recurrent
infections, eczema, thrombocytopenia, and an increased risk
of autoimmunity and malignancy as a result of abnormal
lymphocyte activation. It is an X-linked disease caused by
mutations in WASP, a member of actin regulators that
function as scaﬀolds transducing a wide range of signals
between proteins or from proteins to membranes to mediate
dynamic changes in the actin cytoskeleton [80].
WASPfunctionsinmultiplecellularprocessesinimmune
responses. It links the T-cell receptor (TCR)/CD3 complex
to the actin cytoskeleton, enhancing the eﬃciency of the
immunological synapse formation and cytokine secretion
[81]. It also promotes homeostasis of regulatory T-cells and
controls T-cell activation and eﬀector functions [80, 82].
Most WASP molecules in the cytoplasm of T cells are
associated with WASP-interacting protein/WIP, which acts
as a chaperone to localize WASP to areas of active actin po-
lymerization including the immunological synapse [83, 84].
Absence of either WASP or WIP induces impaired T cell
proliferation in response to TCR/CD3 ligation as well as6 International Journal of Peptides
defective T-cell homing. Importantly, WASP levels can be
restored to normal by expressing WIP in WIP-deﬁcient cells
suggesting that the WIP stabilizes and regulates the absolute
cellular levels of WASP [85, 86].
The WIP has also been shown to aﬀect T-cell activation
independent of WASP [86]. In resting cells, WIP remains in
a complex with WASP and an adapter protein, CrkL [83].
In activated T cells, the CrkL interacts with phosphorylated
ZAP-70, a critical adapter molecule near the cell membrane
and recruits the WASP-WIP-CrKL complex to the immuno-
logical synapse [87]. At the synapse, WIP is phosphorylated
by PKCθ, resulting in the release of WASP which upon
activation by the membrane-bound Cdc42 kinase initiates
actin polymerization. Free WIP binds to newly formed actin
ﬁlaments and helps stabilize the immunological synapse
[82, 86]. Furthermore, WIP regulates the activity of the NF-
AT/AP-1 transcription factorcomplex. AP-1 is a heterodimer
of Fos and Jun proteins that both regulate the transcription
of multiple biological mediators including the cell surface
receptors and directly facilitate the entry of T cells into cell
cycle. WIP overexpression is associated with increased actin
stabilization and enhanced AP-1 in activated T cells [88].
Structurally, WASP proteins are multidomain proteins
consistingofaconservedenabled/VASPhomology-1(EVH1)
domain, also referred as the WASP homology 1 (WH1)
domain, a GTPase binding domain, a proline-rich region,
and a basic motif connected through a central region to a
WH-2 motif that binds the actin nucleating complex [80,
82]. Most missense mutations in WAS involve the residues
in the EVH1 domain of WASP [80]. EVH1 domains have
been found in ∼6 3 0h u m a ng e n e sa n da r ec l a s s i ﬁ e di n t o
four distinct protein families based on amino acid sequence
analysis that includes WASP; enabled/vasodilator-stimulated
phosphoprotein (Ena/VASP); Homer/Vesl; sprout-related
proteins with an EVH1 domain (SPRED). Each EVH1
subclass recognizes a distinct pattern of amino acids, but all
of them bind proline-rich sequence in the left-handed PPII
conformation. Residues ﬂanking the PRM contribute to the
binding speciﬁcity of the EVH1 complexes [12].
The primary structure of WIP consists of a highly con-
servedverprolinhomology(VH)domainthatbindsactinﬁl-
aments,multipleputativeSH3-bindingdomainsforinteract-
ing with adapter/signaling molecules and a WASP-binding
domain (WBD) [86, 88] .T h eW B Do fW I Pi sa p p r o x i m a t e l y
30 residues long with a highly conserved central proline-
rich motif and two short epitopes on either side of the
motif. Nuclear magnetic resonance studies and glutathione
S-transferase pull-down assays have demonstrated that the
conserved polyproline motif of WIP occupies the canonical
binding site in the WH1/EVH1 domain of WASP. The WIP
polyproline motif forms a PPII helical turn and straddles
the highly conserved tryptophan side chain of WASP at
the WH1 domain interface, the binding contributing nearly
40% of the total buried surface of the WIP-EVH1 complex
[82, 83, 86, 88]. Secondary structure analysis of the WBD of
WIP by PROSS showed that the residues exhibited φ and Ψ
angles of −65.9 and 157.3, respectively, consistent with PPII
helical conformation [70]( T a b l e s1 and 2). Interestingly, the
WIP polyproline motif has been shown to bind WASP in the
opposite direction through an elongated WBD as compared
with other EVH1:peptide complexes [92]( Figure 2). The
interactions between the conserved phenylalanine residues
in the epitope preceding the polyproline motif and the
hydrophobic surface of the WH1 domain of WASP (Val,
Ala) as well as the formation of a salt bridge between the
conserved glutamine in the binding pocket of the WH1
domain of WASP and the acidic residue (K/R) localized in
an epitope following the polyproline motif of WIP have
been shown to facilitate the reverse orientation [83, 92].
Mutation of WASP residues involved in interaction with any
of the three WIP epitopes reduces the WASP binding. These
structural features support the observations that diﬀerent
missense mutations disrupt the intermolecular interactions
and accelerate degradation of WASP similarly in WAS
patients with diﬀerent genotypes. Thus, the WIP/WASP
structure exhibits semi-independent composite linear motifs
that are recognized in an extended conformation with
enhanced speciﬁcity [12, 80, 86]. A similar example of a scaf-
folding interaction with bidirectional binding of composite
linear motifs has been reported for complexes that regulate
mitogen-activated protein kinase pathways [12, 92].
Recently, it has been reported that treatment with a
peptide derived from the proline-rich WBD of WIP restored
W A S Pt op h y s i o l o g i c a ll e v e l si nl y m p h o c y t e sf r o mp a t i e n t s
with mutations in the WBD of WASP. Furthermore, treat-
ment with the WIP peptide ameliorated the defects in the
reorganization of actin cytoskeleton in T cells from these
patients [93]( Figure 2).
11. PRM:PRD Interactionsin
TranscriptionalRegulation
Eukaryotic gene expression is a dynamic process regulated by
multiplesignalingnetworksmediatedbyrapidandreversible
PPIcomplexes.Formationofternarycomplexesoftranscrip-
tional regulatory proteins is critical for gene transcription.
These complexes include cross-talk between diﬀerent fami-
lies of transcription factors and the interactions of transcrip-
tion factors with coactivators or corepressors. Transcription
initiation requires the formation of an initiation complex
that consists of RNA polymerase II, the basal transcription
machinery (made up of TFIIA, TFIIB, TFIID, TFIIE, TFIIF,
and TFIIH), and the sequence-speciﬁc promoter binding
transcription factors [94]. Many transcription factors medi-
ate transcriptional activation by interacting through their
transactivation domain with one or more components of
the basal transcription machinery. Such direct interactions
are thought to bring the activation domain over large
distances into close proximity with the initiation complex
close to the transcription start site [95]. In this context,
it is interesting to note that PRMs have been frequently
observed in many transcription factors suggesting that the
ﬂexibility oﬀered by such segments potentially contribute
to the interactions involved in the formation of functional
multiprotein transcriptional complex [96].International Journal of Peptides 7
(a) (b)
Figure 1: (a) represents the solution structure of the CD152:CD80 complex (PDB1I8 L), and (b) represents the complex of ICOS:ICOS L.
Homology modeling of ICOS and ICOSL was predicted using the structures of CD152 (PDB 1AH1 and PDB 1DQT), CD80 (PDB 1DR9)
respectively, as templates by Geno 3D [89] and SWISS MODEL [90]. Prediction of the structural complex was performed by ClusPro [91],
the complex with least energy is shown.
Figure 2: PDB 1MKE depicting the solution structure of
WASP:WIP complex, the PRM is labeled.
12. PRM in p300:p53 Interactions
T h ep 3 0 0p r o t e i ni sav e r s a t i l ec o a c t i v a t o rw i t hs e v e r a lc o n -
served domains including the bromodomain which rec-
ognizes acetylated residues; cysteine-histidine-(CH-) rich
domains; a KIX domain; an ADA2 homology domain.
While the amino and carboxy termini of p300 activate tran-
scription, the histone acetyltransferase activity is medi-
ated by the central region. The modular organization of
p300 provides a scaﬀold for assembly of multicomponent
coactivator complexes that regulate transcription through
multiple mechanisms. These include providing a scaﬀold for
recruiting many transcription factors, acting as a bridge to
connect sequence speciﬁc transcription factors to the basal
transcription apparatus, mediating complete activation of
select transcription factors via an intrinsic histone acetylase
activity,aswellasinﬂuencingchromatinactivitybymodulat-
ing nucleosomal histones [97]. Interestingly, phage-peptide
display analysis suggested that the p300 protein exhibits a
strong aﬃnity to bind proline rich peptides [98].
The p53 is one of the most well-studied eukaryotic
transcription factors that functions as a homotetramer. It is
upregulated in response to cellular stress and induces up- or
downregulation of genes involved in cell cycle arrest, DNA
repair, apoptosis, antiangiogenesis, and senescence pathways
[99]. Structurally, it has a modular domain architecture
consisting of independently folded DNA-binding domain
and tetramerization domains ﬂanked by natively unfolded
regions in the amino and carboxy termini. Activation of p53
is associated with various posttranslational modiﬁcations
of multiple lysine residues at the carboxyl terminus. The
amino terminus consists of an acidic transactivation domain
(TAD) including a proline-rich region. The TAD binds many
components of the transcription machinery including the
coactivators p300/cAMP-response element binding protein
(CREB), binding protein (CBP), as well as the negative
regulators MDM-2 [99, 100]. The binding with p300 is
essential for the transcriptional function of p53 [98].
The p300 binds the carboxy terminal regulatory domain
of p53 predominantly via its bromodomain [99]. This
docking releases the p53 of its intrinsic conformational
constraints, allowing phosphorylation of critical threonine
and serine residues in the activation domain, thus facilitating
stabilization. Additionally, the TAD at the amino terminus
of p300 interacts with the proline-rich “PXXP” motifs of
the p53 activation domain [99, 100]. The binding of the
amino and carboxy termini of the p300 with the transacti-
vation regulatory regions of p53 induces a conformational
alteration that promotes the sequence-speciﬁc DNA binding
of p53. The acetylation of critical lysine residues of p53 by
the histone acetyltransferase activity of p300 then promotes
the transcriptional activity. This concomitant binding of
p300 to a relatively ubiquitous proline repeat motif and the
classichydrophobicLXXLLmotifofthep53terminalregions
highlights an additional layer of combinatorial regulation
of the core p300 protein-protein interactions at a promoter
region [98, 101]. Chromatin immunoprecipitation studies
showed that the deletion of the proline repeat motif of p53
prevents DNA-dependent acetylation of p53 by occluding
p300 from the p53-DNA complex [98]. Although the
pathological role of p53 in many neoplasms has been well
characterized, the mechanisms of DNA damage and the
contribution of abnormal p53 in autoimmune inﬂammatory
diseasessuchasulcerativecolitisandrheumatoidarthritisare
recently recognized. Intriguingly, peptides derived from the
“PXXP” containing proline repeat domain of p53 have been
shown to bind p300 and inhibit sequence-speciﬁc DNA-
dependent acetylation of p53 [98].8 International Journal of Peptides
13.Glucocorticoid-Induced LeucineZipper:
p65 Interaction
The mammalian NF-κB family of inducible transcription
factors is responsible for regulating speciﬁc sets of genes in
many cell types and participates in many cellular processes,
including inﬂammation, proliferation, and cell survival. The
most common form of NF-κB is a p65:p50 heterodimer,
which in resting T cells remains in the cytoplasm as an
inactive complex bound to the IκB inhibitor proteins. Fol-
lowing T-cell activation, degradation of IκBr e l e a s e sN F - κB,
allowing the subunits to translocate to the nucleus [102].
The ability of p65 to recruit the histone acetyltransferase
activity-associated complex consisting of p300 and other
coactivators within the nucleus governs the transcriptional
regulation. The p300 induces acetylation of a critical lysine
residue in the rel homology domain of p65 which then
binds to speciﬁc sites in the promoter regions of target DNA
elements and transiently activates transcription of proteins
involved in immune or inﬂammatory responses and cell
growth control [103]. Misregulation of NF-κB is linked
to a wide variety of human diseases including infections,
inﬂammatory autoimmune disorders, and various cancers.
Hence, speciﬁc inhibitors of this nuclear factor are being
sought and tested as treatments [104].
Glucocorticoids are well characterized anti-inﬂamma-
tory and immunosuppressive agents. Glucocorticoids act
by binding the glucocorticoid receptor in the cytoplasm,
thus activating the receptor, which then translocates to the
nucleus where it suppresses p65 acetylation by competing
with the p300 histone acetyltransferase activity [105]. In
addition, the intranuclear glucocorticoid receptor binds spe-
ciﬁc negative and positive glucocorticoid response elements
in target DNA to directly suppress immune response and to
activate transcription of anti-inﬂammatory genes [106].
The glucocorticoid-induced leucine zipper (GILZ) was
recently identiﬁed during a systematic study of genes tran-
scriptionally induced by glucocorticoids [107]. Expression
of GILZ is downregulated following T-cell activation [108].
Blockade of T-cell activation either by interfering with T-
cell costimulatory molecules or by blocking intracellular
signaling pathway has been shown to upregulate GILZ
[74, 108]. In addition, treatment with exogenous GILZ has
been shown to suppress inﬂammatory responses [109–111].
Mechanistically, GILZ-mediated eﬀects on immune and
inﬂammatory responses have been attributed to its ability to
inhibit NF-κBa c t i v a t i o n[ 112].
GILZ has been shown to physically bind the p65 subunit
of NF-κB through a protein-protein interaction [113]. Since
the interaction is independent of the rel-homology domain
and the phosphorylation of inhibitory proteins, it has been
suggested that the GILZ binds the transactivation domain
of the p65 molecule. Analyses of structural complexes of
interactions wherein the binding depends on the presence
of one or more prolines have shown that the functionally
critical proline/s in the interface of one protein often are in
contact with aromatic residues from the other component
[114]. In this context, it is interesting to observe that
Figure 3: The GILZ:p65 complex: homology modeling of GILZ
and p65 was predicted using the structures of delta sleep inducing
peptide(PDB:1DIP)and (PDB:2IW3),respectively, astemplates by
Geno 3D [89] and SWISS model [90]. Prediction of the structural
complex was performed by ClusPro [91]; the complex with least
energy is shown.
p65-transactivation domain that potentially interacts with
the GILZ-COOH presents two highly conserved aromatic
residues, F534 and F542,w h i c ha r ec r i t i c a lr e s i d u e sf o rp 6 5
transactivation [115]. Structure prediction of p65 and GILZ
were generated by homology modeling using Geno3D and
Swiss model protein structure prediction servers [89, 90]
(data not shown). Docking of p65 with GILZ suggested that
the Pro-120 of GILZ was within 5 ˚ A distance of F534 of p65
TAD [91]( Figure 3).
The primary sequence of GILZ consists of an amino
terminal leucine-zipper motif and a proline-rich carboxy
terminus. Mutationalanalysislocalized the site of interaction
with the p65 to the proline-rich carboxy terminus of GILZ
(GILZ-COOH).TheGILZ-COOHconsistsofthreeconsecu-
tive (PXX) motifs with a proline as every third residue [110].
Secondary structure assignment based on backbone dihedral
angles by PROSS showed that the Pro120 of GILZ exhibited a
φ angle of −67◦ ±5◦ and a Ψ angle of 142.5◦ ±15◦ (Tables 1
and 2), thus adopting a PPII helical conformation [70].
Additionally, the presence of multiple glutamic acid residues
in the region increases the net charge further promoting
the extended conformation by electrostatic repulsion [116].
Recently, a small peptide mimic of GILZ, GILZ-P, has been
developed by conceptually integrating the mechanism of
action glucocorticoids and the knowledge derived from the
structural analysis of GILZ and its interaction with the p65
subunit of NF-κB. Treatment with GILZ-P suppressed T-cell
activation and inﬂammation in a mouse model for multiple
sclerosis[117].Itisspeculatedthatthelow-molecular-weight
GILZ-P can provide promising leads for developing small
molecule NF-κB inhibitors.
14. Silencing Mediator for
RetinoicandThyroidHormone Receptors
(SMRT) and p65 Interaction
As stated above, the regulated activation and repression
of transcription are critical in many biological processes.
Controlled repression of transcription is observed in cell-fate
decisions during development and cellular diﬀerentiation, asInternational Journal of Peptides 9
well as in the maintenance of homeostasis [94]. SMRT and
nuclear receptor corepressor (NCoR) are large homologous
corepressor proteins that mediate transcriptional repression
by many diﬀerent nuclear receptors [118]. SMRT and NCoR
are also recruited by many other DNA-binding transcription
f a c t o r s ,s u c ha sB C L 6 ,K a i s o ,E T O ,M E F 2 C ,C N O T 2 ,a n d
CBF1. Mechanistically, SMRT and NcOR complexes asso-
ciate with histone deacetylase (HDAC) enzymes and mediate
transcriptional repression through deacetylation and con-
densation of chromatin [119].
Consistent with observation that the acetylation of p65
governs transcriptional activation, the components of a
corepressor complex for NF-κB include HDAC, SMRT, and
NCoR [120]. SMRT and NCoR do not exhibit an enzymatic
activity but trigger the catalytic activity of HDAC. The
SMRT-HDAC complex is responsible for basal repression
of classical NF-κB-regulated gene targets in the unstimu-
lated state [121]. In resting cells, NF-κB remains in the
cytoplasm complexed with the IKBα and IKBβ heterodimer.
Following stimulation, the IκB kinase-α (IKK) and IKKβ
mediate phosphorylation of the IκB proteins and release
the NF-κB subunits for nuclear translocation [102]. The
IKKα phosphorylates SMRT and initiates derepression, thus
preventing HDAC chromatin association. This allows the
active p50-RelA/p65 of NF-κB to bind DNA and potentiate
transcription [118, 119, 122]. Thus, the SMRT-dependent
transcriptional regulation of NF-κB plays a critical role in
controlling cellular proliferation.
Structurally mammalian SMRT has two amino terminal
SNT (Swi/Ada/N-CoR/TFIID)/DNA-binding domains and
two receptor interaction domains that present corepressor
nuclear receptor (CoRNR) motif near the carboxy terminus
[119, 121]. In addition, SMRT also contains three repression
domains (RDs) that recruit diverse proteins. The third RD
domain of SMRT includes proline-rich regions and has been
shown to mediate transcriptional regulation by interacting
withtheligand-activatedglucocorticoidreceptor[120].Yeast
two hybrid system and glutathione S transferase pull-down
assays showed that the residues encompassing the proline
rich SMRT RD3 region speciﬁcally and selectively bind the
residues of the transactivation domain of p65. Signiﬁcantly
treatment with SMRT peptide derived from this proline-
rich region has been shown to physically interact with the
p65 and inhibit transactivation of inﬂammatory proteins via
recruitment of HDACs [123]( Figure 4).
15. MYND:PRM Interactions
The MYND domain is a zinc-binding domain present in a
large number of proteins that participate in many protein-
protein interactions involved in transcriptional regulation.
Some of the proteins with MYND domain include BS69, a
transcriptional corepressor; the chimeric fusion protein of
acute myelogenous leukemia (AML) and ETO (a nuclear
protein that interacts with corepressor molecules) (AML-1-
ETO); the bone morphogenesis protein receptor-associated
molecule 1 (BRAM1), deformed epidermal autoregulatory
factor-1 (DEAF-1), and SET and MYND domain-containing
proteins (SMYD) [124–126]. Functionally, many MYND
Figure 4: SMRT: p65 complex: the SMRT structure was derived
from the Chain A of the PDB 2ODD. Homology model of p65 was
predicted using the structures of PDB:2IW3 as templates by Geno
3D by Geno 3D [89] and SWISS MODEL [90]. Prediction of the
structural complex was performed by ClusPro [91], the complex
with least energy is shown.
domain containing proteins have been involved in diverse
cellular processes including proliferation, apoptosis, adhe-
sion, and migration. Although the role of most MYND
domainshasbeeninvestigatedwithrespecttotumorigenesis,
their role in hematopoietic development suggests a potential
role in normal immune response as well as in immunopa-
thology [127, 128].
The MYND domain typically recognizes proline-rich
motifs in partner proteins. For example, molecular studies
have shown that the BS69 MYND binds the viral oncopro-
teinsEA1andEBNA1aswellastheMyc-relatedcellulartran-
scription factor (MGA) through “PXLXP” motif conserved
in all three interacting partners [124]. The chimeric AML1-
ETO protein contains the DNA-binding domain of AML1
andnearlyallofETO[129].TheETOhostsaMYNDdomain
at the carboxy terminus and has been shown to physically
associate with N-CoR/SMRT and their associated HDACs
to aberrantly repress transcription [130]. Mutational studies
suggested that the proline-rich motif “PPPLI” in the SMRT-
RD3 speciﬁcally interacts with the ETO MYND domain
[131]. Interestingly, a peptide derived from the SMRT-RD3
has been shown to speciﬁcally bind the MYND domain of
AML/ETO. Solution structure of the MYND-SMRT peptide
complexsuggestedthattheSMRTPRMbindsinanextended
conformation to a hydrophobic pocket in MYND [130]
(Figure 5). The φ and Ψ angles of the critical proline residues
areconsistentwithPPII helicalconformation(Tables1and2)
[70]. The side chain of the critical proline in the SMRT PRM
is packed on top of a highly conserved tryptophan in the
ligand-binding region of the MYND domain. The carbonyls
of the second and third prolines of the SMRT PRM form
hydrogen bonds with the conserved glutamine and serine
residues of the MYND domain at the binding interface.
Although hydrogen bonds to the backbone generally cannot
provide speciﬁcity, the relative geometrical positions of
the highly conserved tryptophan, glutamine, and serine in
MYND-binding domain are thought to favor interaction
with the elongated conformation of the SMRT/NcOR PRM
[130].
Since transcriptional regulation involves direct interac-
tions between the transactivation domains of a transcription10 International Journal of Peptides
Figure 5: The SMRT:MYND complex (PDB 2ODD) with proline
in the interface highlighted.
factor with either coactivators/corepressors in the tran-
scriptional machinery to initiate or suppress transcription,
molecules that directly block the formation of these com-
plexes would then function as transcriptional modulators
[132]. Peptides or small molecule mimics of the transac-
tivation domain of transcription factors should be able to
competitively interfere with its natural counterpart. How-
ever, translation of this concept has been highly challenging
as evidenced by the few synthetic transactivation domain
inhibitors reported in recent years.
16. Conclusion
Increasing knowledge of the interactome in the physiological
and pathological immune responses provides an unprece-
dented opportunity for identiﬁcation and characterization
of potential diagnostic and therapeutic targets. Although,
it is recognized that protein-protein interaction interfaces
may be dissected into much smaller contact points, and
only a small number of amino acids are critical to the
speciﬁcity of the interactions, comprehensive rules are still
diﬃcult to derive [133]. Despite this, an often used strategy
in the discovery of peptide drugs is an exploitation of
the complementary surfaces of naturally occurring binding
partners. It is expected that these peptides function as com-
petitive inhibitors, masking an interaction site and making it
inaccessible for the binding of the protein from which it has
beenderived.Theinhibitorypeptidescouldserveaspotential
drugs by themselves, and also more importantly, knowledge
about the structure of the critical amino acids at the interface
could be used as a basis to design a collection of potential
mimetics [134].
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